Alere Receives FDA Clearance for Influenza A & B 2 Test

Oct 02, 2017

NEW YORK (GenomeWeb) – Alere said today the US Food and Drug Administration has granted 510(k) clearance of its Alere i Influenza A & B 2 test for the faster detection of influenza A and B infection in children and adults.

Alere said that the test is a second-generation rapid molecular assay that delivers lab-accurate results and has the ability to report a positive result in as little as five minutes.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Menu

Alere Receives FDA Clearance for Influenza A & B 2 Test

To read the full story....

Breaking News

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

In Brief This Week: Invivoscribe, Todos Medical, Personalis, and More

FDA Approves CD Diagnostics' Test for Prosthetic Joint Infections

FDA Clears InBios International Zika Antibody Test

Beckman Coulter Life Sciences Recalls Hematology Analyzers Due to Risk of Inaccurate Results

Featured White Papers

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Clinical Genomics of NTRK Fusion Detection in Cancer

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

What's Popular?

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

Roche Obtains FDA Clearance for Sexually Transmitted Disease Test

FDA Clears Cepheid, Hologic CT/NG Assays for Extragenital Testing

Guardant Health Prices $319.5M Public Stock Offering

Sponsorships